Ausgabe 4/2019
Inhalt (13 Artikel)
Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis
Lakshmi Narasimha Thota, Thiruvelselvan Ponnusamy, Xinjie Lu, Lakshmi Mundkur
Resolvin D1 Attenuates Myocardial Infarction in a Rodent Model with the Participation of the HMGB1 Pathway
Rui Liu, Zhenkun Li, Qiang Wang
Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia
Coline Nydegger, Antonio F. Corno, Ludwig K. von Segesser, Maurice Beghetti, Michele Samaja, Giuseppina Milano
Obesity-Related Genetic Determinants of Heart Failure Prognosis
R. M. Agra, M. Gago-Dominguez, B. Paradela-Dobarro, M. Torres-Español, L. Alvarez, A. Fernandez-Trasancos, A. Varela-Roman, M. Calaza, S. Eiras, E. Alvarez, A. Carracedo, J. R. Gonzalez-Juanatey
Safe and Efficacious Use of 1-Month Triple Therapy in Patients with Atrial Fibrillation and High Bleeding Risk Undergoing PCI
Antonia Sambola, Héctor Bueno, Berta Miranda, Adrian V. Hernandez, Javier Limeres, Bruno García del Blanco, David García-Dorado
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Munemitsu Otagaki, Koichiro Matsumura, Hiromi Kin, Kenichi Fujii, Hiroki Shibutani, Hiroshi Matsumoto, Hiroki Takahashi, Haengnam Park, Yoshihiro Yamamoto, Tetsuro Sugiura, Ichiro Shiojima
Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease
Efstratios Koutroumpakis, Elvira O. Gosmanova, Heather Stahura, Stephanie Jou, Rabah Alreshq, Ashar Ata, Mandeep S. Sidhu, Edward Philbin, William E. Boden, Radmila Lyubarova
Effect of a Therapeutic Strategy Guided by Lung Ultrasound on 6-Month Outcomes in Patients with Heart Failure: Randomized, Multicenter Trial (EPICC Study)
Manuel Méndez Bailón, Jose María Cepeda Rodrigo, Noel Lorenzo-Villalba, Jose Manuel Cerqueiro, Jose Curbelo García, Elpidio Calvo Manuel, Francisco Javier Martín-Sánchez, Ramon Bover Freire, Pilar Cubo Romano, Luis Manzano Espinosa, Jose Carlos Arévalo-Lorido, Jose Manuel Casas Rojo, Juan Torres Macho
Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial
Gavin A. Lewis, Erik B. Schelbert, Josephine H. Naish, Emma Bedson, Susanna Dodd, Helen Eccleson, Dannii Clayton, Beatriz Duran Jimenez, Theresa McDonagh, Simon G. Williams, Anne Cooper, Colin Cunnington, Fozia Zahir Ahmed, Rajavarma Viswesvaraiah, Stuart Russell, Stefan Neubauer, Paula R. Williamson, Christopher A. Miller
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis
Zheng-Wei Chen, Cho-Kai Wu, Yao-Hsu Yang, Jenq-Wen Huang, Vin-Cent Wu, Jen-Kuang Lee, Pau-Chung Chen, Yen-Hung Lin, Lian-Yu Lin
Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019
Lane Zhang, David A. Steckman, Evan C. Adelstein, Joshua Schulman-Marcus, Alfred Loka, Roy O. Mathew, Ferdinand J. Venditti, Mandeep S. Sidhu
The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury
Vince Siebert, Joseph Allencherril, Yumei Ye, Xander H. T. Wehrens, Yochai Birnbaum
After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
Andrea Rubboli, Matteo Lisi